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EDITORIAL REVIEW
Renal bone disease 1990: An unmet challenge
for the nephrologist
The replacement of excretory kidney function by dialysis or
by renal transplantation has not only improved the survival of
the patients with end-stage renal failure, but has revealed a
variety of other complications which represent a formidable
challenge for the nephrologist.
Abnormalities in mineral metabolism and bone are responsi-
ble for a considerable part of the morbidity and mortality
encountered in these patients. These problems are related
either to the failing excretory and/or endocrine functions of the
kidney or to side-effects of therapeutic measures calling for
reconsideration of formerly widely accepted therapeutic prac-
tices.
A rational approach to the treatment of renal bone disease
requires a basic understanding of: (1) the anatomic physiology
of bone; (2) the pathophysiologic effects of renal failure on
mineral metabolism and bone; and, (3) careful assessment of the
various available therapeutic modalities.
Anatomic physiology of bone
Functions of bone
The skeleton has a dual mechanical and metabolic function in
the body. The hardness and rigidity of bone provide internal
support for soft tissue and protection to vital organs and
blood-forming tissues. Muscle and tendon insertion on bone
transmits the force of muscular contraction.
In addition to these mechanical functions, the microscopic
structure of bone, its high mineral content and close contact to
extracellular fluid (ECF) allow bone to play an important
metabolic role in the homeostatic regulation of calcium concen-
trations in body fluids and tissues. In a normal individual,
approximately 110 nmoles of calcium enter and leave bone daily
[11.
There is a dynamic interaction between these two functions.
A prolonged demand for calcium will tax the mechanical
strength of the skeleton by depleting its mineral content and
affecting its hardness. Demineralized bone is at risk for mechan-
ical failure and fracture.
Macroscopic structure of bone
On the macroscopic level, compact or cortical bone is distin-
guished from trabecular or cancellous bone. Both compact and
spongy types are found in nearly every bone. Compact bone
accounts for 75% of total bone volume [2]. The strength and
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rigidity of the long bones of the appendicular skeleton are due to
compact bone.
Cancellous bone is found primarily in the axial skeleton, and
consists of branched, anastomosed bony trabeculae that create
interconnected spaces continuous with the marrow cavity of
long bones. The surface area of the trabeculae accounts for
approximately 60% of the total surface area of the skeleton. It
is the labyrinthine structure of spongy bone that facilitates its
central role in mineral metabolism by providing a large surface
area for ion exchange.
Biochemistry of bone
Bone consists of an organic intercellular matrix in which a
mineral, nonorganic material is deposited. Type I collagen
represents 90% of the bone matrix and is associated with an
array of non-collagenous proteins, to include: fibronectin, os-
teonectin, bone Gla-protein (BGP), bone proteoglycan and
sialoprotein [3]. Although the physiological role of the non-
collagenous proteins is unclear, BGP [4, 5] and osteonectin [6]
have been used as markers due to their specificity and the fact
that they can be quantified in bone and sera samples.
The mineral phase is formed of crystals of calcium phosphate
and carbonate-containing apatite of different size and perfection
[7]. The exact mechanisms by which mineralization occurs on
and within the collagen matrix is not fully elucidated. However,
it is well established that the apatite crystals and more primitive
calcium phosphate salts (brushite) provide a huge surface for
exchange of bone-seeking elements. In addition to calcium,
phosphate and hydroxyl, numerous other compounds can be
adsorbed or incorporated into the apatite crystals. Some are
normal constituents of the body such as sodium, magnesium,
potassium, zinc, fluoride and silicon, while others are toxic or
inhibitors of mineralization, to include: aluminum, pyrophos-
phates, diphosphates, phosphocitrate, and lithium [8, 9].
Tetracycline has been used as a means to assess mineraliza-
tion status and mineral or bone apposition rate. Tetracyclines
are autofluorescent antibiotics and their uptake in bone is seen
as bright yellow lines under fluorescent light microscopy (Figs.
IA, 2A, 3, 4). The mineralization rate during a given period of
time can be determined by administration of tetracycline at
specific intervals and measurement of the width between the
resultant areas of labelled bone [10].
Microscopic structure of bone
The amount of organic matrix determines bone volume as
assessed by histomorphometry. Normally 80 to 90% of the
matrix is mineralized and RI to 20% is formed of collagen
strands soon to be mineralized (osteoid).
Generally, the amount of mineralized matrix determines the
mechanical strength of the skeleton. However, in pathological
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Fig. 1. Predominant hyperparathyroid bone
disease. A. Increased fraction of trabecular
surface exhibiting tetracycline uptake.
Presence of diffuse intense broad single labels
in woven bone and irregular double labels.
tJndecalcified, unstained 7;tm thick section
viewed under fluorescent light microscopy.
Original magnification: 12x. B. Irregular
trabecular surface with increase in osteoid.
Abundance of osteoblarts and osteoclasts.
Marrow fibrosis. Undecalcified, 3 .un thick
section. Modified Masson-Goidner trichrome
stain. Original magnification: 8x.
Fig. 2. Low turnover osteomalacia. A. Thin
single labels at the bone-osteoid interface.
Absence of double labels. Undecalcified,
unstained 7 m thick section viewed under
fluorescent light microscopy. Original
magnification: 20x. B. Dramatic increase in
extent of osteoid covering the trabecular
surface, and thick osteoid seams. Absence of
osteoblasts and osteoclasts. Undecalcified, 3
tm thick section. Modified Masson-Goldner
trichrome stain. Original magnification: 8 x.
Fig. 3. Mixed uremic osteodystophy. A.
Coexistence of double and thin single
tetracycline labels. Undecalcified, unstained 7
m thick section viewed under fluorescent
light microscopy. Original magnification: 12x.
B. Increase in osteoid surface and extent of
resorption lacunae. Mild peritrabecular
fibrosis. Undecalcified, 3 m thick section.
Modified Masson-Goldner trichrome stain.
Original magnification: 8x.
Fig. 4. Double tetracycline labelling. Two
regular distinct labels. The outer golden-
yellow label represents incorporation of
demeclocycline, the inner green-yellow label
tetracycline hydrochloride incorporation. The
nonfluorescent zone between the labels
represents the amount of bone mineralized
during the labelling free interval.
Undecalcified, unstained 7 m thick section
viewed under fluorescent light microscopy.
Original magnification: 32 x.
Fig. 5. Aluminum deposits in bone. Linear
intense blue aluminum staining at the bone-
marrow interface, bone-osteoid interface, at
cement lines and within bone. Diffuse light blue
aluminum staining within bone. Undecalcified, 7
.an thick section. Modified Solochrome
Azurine. Original magnification: 8 x.
states and especially in renal osteodystrophy, the quality of the
bone texture has to be taken into consideration [II]. Lamellar
arrangement of mineralized collagen bundles ensures optimal
hardness and elasticity of hone. In states of local or systemic
high turnover of bone, the collagen fibers are deposited in a
loose and randomized manner. The fibrils lack the typical
birefringence under polarized light microscopy and display a
crisscross, "woven" pattern. In addition to its deficiency in the
optimal arrangement of the collagen fibers, mineralization of
woven bone is deficient and haphazard, and as a result woven
bone is brittk. This explains why some renal patients present
with deformities and fractures even though their bone volume
or bone density is normal or high. Careful assessment of the
effects of therapeutic modalities is essential, as medication may
leave unchanged the total osteoid volume and bone mass but
may favor one or the other structural pattern, that is, woven or
lamellar bone, which can be of biomechanical relevance.
Modelling and remodelling of bone
Bone ,nodelling describes the process of bone growth. There
are two types of bone growth, longitudinal and appositional.
Longitudinal growth occurs by enchondral ossification; apposi-
tional growth takes place by periosteal apposition of new bone
and endosteal resorption of old bone. The resorbing and forma-
tion processes are not coupled and occur at different sites.
The adult skeleton is not a static tissue but undergoes
continual remodelling, that is, removal of bone and apposition
of new mineralized matrix. This dynamic process allows for
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removal of older bone whose mechanical competence may be
weakened by fatigue damage [12], and formation of new bone
with a lower mineral density which can serve as a readily
available source of calcium for the organism [13]. Normally,
approximately 80% of the bone surfaces is quiescent. The
remainder of the surface is the site of active remodelling Ill,
14]. The remodelling cycle, which normally lasts from four to
eight months [11, 14], encompasses several phases: (a) an
activation phase where osteoclasts are recruited and the bone
surface prepared; (b) a resorption phase where the osteoclasts
contact and erode the bone surface; (c) a reversal phase when
resorption ends and osteoblasts start to appear at the site; and,
(d) formation and mineralization of bone.
Resorption always precedes and is usually coupled with bone
formation. The number of active remodelling sites (bone turn-
over), the effectiveness and the duration of each phase can vary
greatly in pathological conditions and the derangements repre-
sent the basis of metabolic bone diseases.
It must be emphasized that the amount of bone resorbed or
formed depends not only upon the number of bone cells
involved in the process but also their individual activity, the
way they interact, and their life span.
Bone cells
There are two primary endogenous bone cell types which
have a contrasting and coordinated function. The osteoclasts
are responsible for bone degradation, and the osteoblasts are
involved in bone formation and mineralization. Two other bone
cells are encountered in bone, the lining cells and the osteo-
cytes. Recently, strong evidence has been gathered pointing to
the involvement of other cell lines from the bone marrow and
the immune system in the regulation of the remodelling process.
Osteoclasts. The osteoclasts are large, usually multinucle-
ated cells. After years of searching for the ontogeny of this cell
type, a large body of evidence has been gathered pointing to a
monocyte-macrophage lineage [15—17]. Preosteoclasts are
thought to be derived from immature mononuclear cells within
the hematopoietic system and fuse to form mature osteoclasts.
The morphological specific characteristic of an active osteo-
clast is the ruffled border surrounded by an organelle-free clear
zone containing actin [181. The ruffled border is in contact with
the bone surface and is the site of bone resorption.
Recent work has shown that in addition to the classical
theory of acid bone solubilization by activation of lysosomal
enzymes and excretion of hydrogen ion [19], additional factors
are involved in the cellular mechanisms of bone resorption. The
role of carbonic anhydrase, cathepsins and calcium-sodium ion
exchange mechanisms have been determined. Moreover, a
complete or partial blockage of resorption has been found in
vitro and in vivo studies when inhibitors of these substances
and mechanisms were administered [20—231. However, these
new potential therapeutic approaches need to be confirmed and
tested further.
Osteoblasts. Osteoblasts are mononuclear, cuboidal cells (15
to 20 m) found on the advancing surface of growing bone.
Osteoblasts are rarely seen isolated. They form a monocellular
layer arranged in a palisade-like manner and resemble an
epithelium. However, they do not display the characteristics of
a true epithelium since adjacent cells make contact by gap
junctions [241 and a basement membrane is absent. Therefore,
there is no continuous barrier between osteoblast and bone
marrow [25]. They originate in the bone marrow from stromal
fibroblast-like cell precursors and possess a "characteristic
repertoire of macromolecular synthetic mechanisms and hor-
monal receptors" [26].
Osteoblasts produce mineralized bone matrix. They secrete
Type I collagen fibers and non-collagenous proteins and are rich
in alkaline phosphatase. The mechanisms of action or interac-
tion of this cell type with crystal nucleation and perfection are
still not fully elucidated. Osteoblasts may be involved in the
removal of inhibitors of nucleation, such as pyrophosphates
[27]. However, their ability to transport ionized calcium to the
mineralization front has not been proven [281.
Lining cells. The bone surfaces not involved in the remodel-
ling process are covered by a thin, unmineralized layer of
collagen fibers, the lamina limitans, and by an envelope of flat,
elongated cells, the lining cells. The thin layer of lining cells
represent the barrier between bone and marrow. These cells are
thought to be of osteoblastic origin representing a terminal or
"resting osteoblast" [2]. These cells do not present histological
signs of activity and were thought to have little or no role in
bone metabolism. Recent evidence suggests that when acti-
vated, these cells are involved in the process of preparing the
bone surface prior to resorption and may have a role in the
coordination between the other bone cells and are implicated in
the control of calcium fluxes across the blood-bone barrier
(v.i.).
Osteocvtes. Approximately 10% of osteoblasts bury them-
selves into the bone matrix and become osteocytes. The osteo-
cytes are connected to each other and to superficial lining cells
through extended cellular processes that traverse bone within
thin canaliculi. The osteocytic/lining cell network offers a large
surface area for ion exchange and seems to be involved in the
rapid mobilization of calcium [29].
Interaction between bone cells. Despite their different origin
and function, osteoclasts and osteoblasts are not independent
from each other. As previously postulated by Rodan and Martin
[30], phenomena or agents stimulating bone resorption do not
act directly on osteoclasts but via other cells including osteo-
blasts and lining cells. The action of resorbing substances" in
cell cultures has been proven inefficient in culture containing
only osteoclasts [31]. Signs of activity are obtained only when
osteoblasts or other cells are included [32).
Receptors for parathyroid hormone (PTH) and 1 ,25(OH)2D3
have been isolated in osteoblasts, whereas, it has not been
possible until now to demonstrate them in osteoclasts. The wide
variety of so-called resorptive agents induce morphological and
metabolic changes in osteoblasts in vitro. In vivo, serum levels
of PTH display a stronger relationship to the number of
osteoblasts than osteoclasts [33]. The practical implication of
these new discoveries is that any agent or drug, thought to have
a specific action on one type of cell, will probably act on both
cell lineages.
Other cells. Other cells are known to participate in the
regulation of the remodelling process. Among them, mast cells
via heparin production increase collagenase activity and pro-
mote bone resorption. It has been shown that protamine admin-
istration decreases the resorptive process [34]. The monocyte-
macrophage cell line is thought to act as "coordinator" of local
or systemic signals through its production of prostaglandin,
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interleukin I, l,25(OH)2D3, growth factors, and lymphoid cells,
especially T-lymphocytes via secretion of lymphokines [35, 36].
In practical terms, any derangements of these cell lines or any
therapy aimed at controlling them could have an effect on bone
metabolism.
Role of bone in mineral homeostasis
Bone is quantitatively the primary calcium reservoir of the
body and plays an important role in calcium homeostasis. Even
though plasma calcium is maintained within narrow limits,
circadian variations exist in humans [37, 38] and animals [39,
40]. Circadian periodicities have also been established for bone
cell activity and secretion of PTH, l,25(OH)2D, calcitonin and
BGP [41]. Based on these findings and experimental data, a new
physiological view of in vivo calcium dynamics has been
postulated [42, 43]. In this non-linear model of calcium homeo-
stasis or homeokinesis, the target organs, that is, gut, kidney
and bone, are dynamically adapted to periodic relationships
with the external environment and can even anticipate them.
Spontaneous synchronized flux and efflux of calcium (oscilla-
tions) exist in the different target organs. For example, net
addition of calcium to the ECF through the gut is counterbal-
anced by simultaneous uptake of calcium by bone, and vice
versa. The period, amplitude and phase of these spontaneous
oscillations can be adjusted independently and represent an
extremely flexible system in response to any alteration in
plasma calcium [44]. Therefore, correction of abnormalities in
plasma calcium is not solely regulated by feedback loops and
cannot be accomplished only by bone formation or resorption
[43]. The quiescent surfaces of bone and bone lining cells
sensitive to calciotropic hormones are actively involved in the
constant transfer of calcium into and from bone. Total calcium
flux is approximately 110 nmoles per day of which quiescent
surfaces exchange 100 nmoles, ten times the flux exchanged by
the remodelling surfaces (44]. The simple calcium phosphate
compounds (brushite) represent the primary calcium storage in
the superficial layers of bone.
Factors affecting bone
Parathyroid hormone acts (a) as an activator of bone remod-
elling by increasing the number of osteoblasts and osteoclasts,
and (b) as a modulator of the minute-to-minute regulation of
calcium fluxes across the blood-bone barrier [11, 28]. Actions of
vitamin D metabolites, in particular 1,25(OH),D3 are multiple
and complex [45, 46]. l,25(OH),D5 stimulates the differentia-
tion of many cells [47], enhances directly or indirectly the
activity of bone cells [48, 49] and facilitates mineralization [28].
The primary known effect of calcitonin on bone is inhibition of
osteoclast-mediated resorption [50]. In addition, in vivo and in
vitro findings support the notion that calcitonin stimulates
osteoblasts and may affect bone formation [51—53]. Moreover.
cellular binding sites for calcitonin were described in osteo-
blasts [541. Glucocorticoids, sex hormones, thyroid hormones
and, possibly, insulin and Vitamin A may also modulate bone
turnover [281.
A large variety of local substances participates in the regula-
tion of recruitment and activity of bone cells to achieve contin-
ual remodelling of bone [28]. These local factors mediate and/or
act in conjunction with systemic factors. These substances can
originate from extraskeletal sources, the monocyte-macrophage
cell types or bone cells. They belong primarily to the categories
of growth factors and the prostaglandins. The osteoblast's
ability to secrete I ,25(OH)2D3 directly influences bone remod-
elling [55]. Local electrical potentials, adenosine, fluoride and
pyrophosphate also have a local regulatory effect on bone cell
activity.
Pathophysiologic effects of renal failure
A variety of kidney diseases including tubular defects, renal
stone disease, nephrotic syndrome, kidney transplantation and
oxalosis can induce bone changes. However, the most promi-
nent bone disease occurs in patients with partial or complete
loss of glomerular filtration rate (GFR). This review will focus
on this aspect.
Effects of renal failure on mineral metabolism
With the progressive loss of excretory kidney function,
secondary hyperparathyroidism typically develops early on
[56]. Even though a variety of independent and interrelated
factors have been identified as influencing the hyperparathyroid
state in advanced renal failure, there remains considerable
controversy over the sequence of early events leading to the
increased serum levels of PTH.
Two related factors seem to play a pivotal role in triggering
the excess secretion of PTH: alterations in the excretion of
phosphorus by nephrons and deranged vitamin D metabolism.
Despite the progressive loss of nephrons, serum phosphorus
levels do not rise before the GFR is reduced to levels of less
than 20 to 25% of normal because those nephrons remaining
augment their excretion of phosphorus. The increased phospho-
rus excretion of the remaining nephrons results in reduced
activity of renal C1-a-hydroxylase [57] and, consequently, in
deficiency of the active vitamin D metabolite 1,25(OH)2D3.
The relative or absolute deficiency in I ,25(OH)2D3 levels
leads to increased synthesis and secretion of PTH [58—61]
which, in turn, will stimulate renal production of l,25(OH)2D3
[62, 631 and, possibly, restore the serum levels of l,25(OH)2D to
normal values. This could, in part, explain why serum levels of
1,25(OH)2D3 in early renal failure have been reported to be
either within the normal range [64, 65] or depressed [66, 671.
We advanced the hypothesis that the increase in PTH secre-
tion could act as a compensatory mechanism of nature used to
overcome l,25(OH)2D3 deficiency [11]. What role the extra-
renal production of 1 ,25(OH)2D3 plays in compensating for the
failing kidney's inability to produce the active vitamin D
metabolite needs further study.
With progression of renal insufficiency, the compensatory
effect of PTH on I ,25(OH)D3 deficiency is defeated, and a
relative and, thereafter, absolute deficiency in I ,25(OH)2D3
exists as suggested by the direct relationship between the
decrease in GFR and circulating levels of l,25(OH)2D levels in
patients with mild to moderate renal failure [68]. Deficiency of
l,25(OH),D1 will further stimulate PTH secretion, decrease
intestinal calcium absorption [69, 70] and may induce skeletal
resistance to the calcemic action of PTH [71, 72].
When the kidney can no longer increase the excretion of
phosphorus through the remaining nephrons to compensate for
advanced nephron loss, hyperphosphatemia will ensue usually
associated with hypocalcemia. This decrease in serum calcium
will further stimulate the secretion of PTH. The participation of
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hypocalcemia in maintaining high levels of PTH in the advanced
stage of renal failure is well established. However, its role in the
initial derangement of parathyroid activity is controversial.
It was generally accepted that transient or sustained hypo-
calcemia, due to phosphate retention and/or decreased activity
of 1 ,25(OH)2D3, was the primary factor in the development of
secondary hyperparathyroidism [73, 74]. Even though hypocal-
cemia represents the appropriate signal for increased activity of
the parathyroid glands, some clinical and experimental obser-
vations have challenged this concept.
For example, one prospective study found increased circulating
levels of PTH and hyperparathyroid bone disease with relatively
normal serum calcium levels [75]. Recent experimental studies in
partially nephrectomized dogs fed a normal diet, showed that the
animals developed sustained, elevated total serum calcium asso-
ciated with increased PTH levels and overt hyperparathyroid bone
disease [76]. In another study, nephrectomized dogs given a diet
high in calcium displayed an increase in serum calcium which did
not retard the development of secondary hyperparathyroidism,
the latter being oniy prevented by administration of I ,25(OH)2D3
[77]. This can be explained, at least in part, by the elevated
set-point for calcium-regulated PTH secretion in renal failure [78,
79]. The suppressive action of l,25(OH)2D3 on PTH secretion
seems to be a direct effect of the vitamin D metabolite since
l,25(OH)2D3 receptors have been isolated in parathyroid glands
[801. In addition. 1 ,25(OH)2D3 decreases preproparathyroid hor-
mone messenger RNA [61] and decreases basal, maximally-
stimulated and maximally-inhibited PTH secretion without alter-
ing the set-point for calcium [79].
The increase in bioactive PTH secretion [811 is accompanied
by reduced renal clearance and impaired degradation of PTH
[82, 83]. However, the retained fragments are thought to be
metabolically inactive.
The contribution of metabolic acidosis to the pathogenesis of
renal bone disease has not been fully elucidated and awaits
further study. The role of calcitonin in the early phase of renal
failure is uncertain. In the advanced stage, neither endogenous
nor exogenous calcitonin protects against hyperparathyroid
bone disease [84]. Absence of catabolism of 32-microglobu1in
by the kidney is responsible for deposition of amyloid and may
be responsible for severe bone pain, bone cysts and femoral/
vertebral fractures, in addition to carpal tunnel syndrome and
arthropathy [85, 86].
Instituting various forms of dialysis therapy might alter the
spontaneous course of renal osteodystrophy since dialysis
techniques may influence circulating levels of calcium and
phosphorus. Long-term hemodialysis treatment was reported to
be associated with the development of severe secondary hyper-
parathyroid bone disease [87]. This complication is infrequently
observed, however, probably because the negative calcium
balance is usually avoided in chronically dialyzed patients.
The extracorporeal circuit and, in particular, cuprophan
dialyzer membranes induce activation of the complement [88],
coagulation [89] and contact [90] pathways. Although reuse and
introduction of non-complement activating membranes have
lessened the undesirable reactions, the cumulative effect of
dialysis on neutrophils, monocytes, lymphocytes and platelets
is not negligible [91]. Release of lyzosomal enzymes by neutro-
phils, production of interleukin-l by monocytes, and diminished
production of interleukin-Il by T-lymphocytes could impair the
recruitment and activity of bone cells. In addition, cuprophan
membranes have been implicated in the increased synthesis of
f32-microglobulins through activation of interleukin-I [91] and
may worsen amyloidosis.
Chronic ambulatory peritoneal dialysis bears the risk of
progressive protein loss into the peritoneal fluid, in particular
DBP-bound 25(OH)D3 [92, 93]. Some studies have found indi-
rect evidence of diminished serum binding capacity [94],
l,25(OH)2D1 and 24,25(OH)2D3 [95].
High concentrations of aluminum in the dialysate have been
responsible for severe encephalopathy and/or low turnover
osteomalacia [96]. The systematic use of reverse osmosis
should render this source of aluminum intoxication accidental,
that is, related to isolated glitches of RO systems.
Aside from aluminum-contaminated dialysate, additional
sources of aluminum have been shown to originate from phos-
phate binders containing aluminum, milk formulae [97, 98] and
medications [99]. Even though a short-term experiment using
young, nonuremic dogs [100] suggested that aluminum deposi-
tion is an epiphenomenon, numerous other studies point to a
direct or indirect effect of aluminum on bone [101] (see Alumi-
num-related bone disease).
Effects of rena/failure on bone
Bone is influenced by the cumulative, long-term effects of
metabolic derangement. The long-standing alterations in min-
eral metabolism generated by renal failure have a profound
effect on the skeleton and induce severe systemic metabolic
bone disease, namely, renal bone disease or renal osteodystro-
phy. The modes of response of bone to pathologic conditions is
limited and virtually every metabolic histological abnormality
of bone can be observed in patients with renal failure [11, 26].
Renal bone disease develops in the early stages of loss of
excretory kidney function [102—1051. When the GFR falls to
50% of normal, more than 50% of the patients exhibit abnormal
bone histology [106]. Bone biopsies show signs of excessive
PTH activity on bone with or without mineralization defect.
There is an increase in bone turnover characterized by in-
creased forming and resorbing sites. The volume and surface of
osteoid are augmented and the number of osteoblasts and
osteoclasts is elevated. Woven osteoid appears when the GFR
falls below 40 mi/mm. Endosteal fibrosis can be seen when GFR
is below 30 mI/mm. The mineralization status as measured by
the uptake of tetracycline is usually within the normal range
until the GFR reaches 40 mI/mm. At GFR lower than 40 mI/mm,
some patients exhibit impaired mineralization with a decrease
in the fraction of osteoid surface labelled with tetracycline
[105].
When end-stage renal failure ensues necessitating chronic
maintenance dialytic therapy, nearly all patients have abnormal
bone histology, and approximately 5% have some stainable
aluminum at the mineralization front—a fraction that increases
up to 50% when long-term dialysis patients are studied [106].
Advanced renal bone disease can be subdivided into three
major histological groups: predominant hyperparathyroid bone
disease, low turnover uremic osteodystrophy (osteomalacic and
adynamic renal bone disease) and mixed uremic osteodystro-
phy consisting of mild to moderate hyperparathyroid bone
disease and defective mineralization [11]. Aluminum-related
bone changes can be seen to varying degrees in all three groups.
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Even though these groups do not represent fully separate
entities, and transformation from one form to another can
occur, it is useful to distinguish them since therapy can be
tailored according to the predominant histologic findings. Prev-
alence of the different forms of renal bone disease may vary
depending on environmental factors, aluminum exposure, ther-
apy with vitamin D metabolites, dietary intake, and dialysis-
related factors.
Predominant Jiyperparathyroid bone disease (Fig. 1). This
type of bone disease is encountered when the primary meta-
bolic abnormality is characterized by tong-standing, excessive
PTH secretion. This disease is seen in approximately 5 to 30%
of dialyzed patients and rarely presents before initiation of
dialysis.
The disease is characterized by a marked increase in bone
turnover. The trabecules are irregular in shape and display
numerous abnormal remodelling sites. The bone cells are ab-
normally high in number, irregular in shape and arrangement.
The enlarged osteoclasts are numerous, containing multiple
nuclei with prominent nucleoli. The resorption cavities are deep
and irregular, frequently dissecting or tunnelling the trabecules.
The osteoblasts have lost their regular cuboidal shape and
have become polygonal or spindled-shaped. The nuclei have
lost their polarity and occupy random positions within the
cytoplasm and contain several nucleoli. The palisade-like
monolayer of osteoblasts may be replaced by an atypical
multilayered arrangement of cells with variable orientation
toward the bone surface (from parallel to perpendicular). These
morphological abnormalities of osteoblasts are accompanied by
profound perturbations of their function.
There is an overproduction of collagen resulting in an in-
crease in osteoid surface and volume and, sometimes, thick-
ened osteoid seam. The osteoid formed is primarily of the
woven, irregular type. The collagen fibers are accumulated
toward the bone surface and are deposited between osteoblasts
and toward the bone marrow leading to peritrabecular and bone
marrow fibrosis. In advanced cases, the bone marrow can be
entirely replaced by fibrosis. This reflects both the irregular
activity of disorganized groups of osteoblasts and the dimin-
ished activity of individual cells [11]. It is conceivable that the
cellular hyperplasia might represent a compensatory phenome-
non to cellular insufficiency [11]. The number of osteoblasts
entrapped in bone is increased resulting in numerous and
irregular osteocytic lacunae within woven osteoid and mineral-
ized bone.
The extent and number of mineralizing sites and the mineral
apposition rate are notably increased as documented by tetra-
cycline labelling. However, the deposition of calcium in woven
osteoid proceeds irregularly, incompletely and diffusely. The
findings of thick osteoid seams and irregular, diffuse tetracy-
cline uptake in woven bone are sometimes erroneously diag-
nosed as osteomalacia.
Usually, the marked increase in bone turnover leads to
cancellization of cortical bone causing a net decrease in cortical
bone volume, most notably evident in the appendicular skele-
ton. In cancellous bone, the bone volume depends upon cal-
cium balance. Typically, hyperparathyroid bone disease pre-
sents high bone volume; however, bone volume can be
markedly reduced in cases of malnutrition, immobilization or
other causes [107]. In addition, areas of high bone mass may be
adjacent to pseudocysts consisting primarily of fibrotic or
hyperplastic bone marrow. In any case, bone strength cannot
be equated with high bone mass since the irregular trabeculae
may lose their proper three-dimensional architecture and their
connectivity. Moreover, they are poorly mineralized and con-
sist mainly of mechanically-deficient woven bone. These char-
acteristics create a particularly fragile bone prone to fractures.
Consequently, the use of the term "osteosclerosis" is inappro-
priate.
In early publications, pathologists impressed by the dramatic
hypercellularity of all bone cells associated with fibrosis and
pseudocysts named this type "osteitis fibrosa cystica" implying
an inflammatory process. This designation is misleading and
does not have any pathogenetic relevance. We prefer the term
predominant hyperparathyroid bone disease.
Low-turnover uremic osteodystrophy—Oseomalacic and
adynamic renal bone disease. The other end of the spectrum of
renal osteodystrophy is represented by low-turnover uremic
bone disease. The histologic hallmark of this group is a pro-
found decrease in the number of active remodelling sites.
Although aluminum overload represents the most frequently
observed pathogenetic factor, parathyroidectomy, underlying
disease and medications can account for a significant proportion
of the cases. Approximately 5 to 25% of patients undergoing
chronic maintenance dialysis present with this histological type.
It is rarely seen prior to initiation of dialysis [108].
This type is characterized by a dramatic reduction in the
number of bone-forming and bone-resorbing cells associated
with a significant decrease in bone formation and mineraliza-
tion. The majority of the trabecular bone is covered by lining
cells, and there are few osteoclasts and osteoblasts.
The bone structure is predominantly lamellar and peritrabec-
ular fibrosis is rarely seen. The extent of mineralizing surfaces
is markedly reduced and, usually, only few thin single labels of
tetracycline are observed. These features reflect the marked
decrease in osteoblastic activity.
Depending upon the sequence of events leading to a decline
in the number and/or the activity of osteoblasts, two histologic
subgroups can be identified. When the reduction in mineraliza-
tion is coupled with a concomitant and parallel decrease in bone
formation, the end result is "adynamic uremic bone disease"
where there are few osteoid seams. When the diminution in
mineralization precedes or is more pronounced than the inhibi-
tion of collagen deposition, an accumulation of unmineralized
matrix is seen as a hallmark of low turnover osteomalacia"
(Fig. 2,A, B).
The increased lamellar osteoid volume is due to the presence
of wide osteoid seams covering a large portion of the trabecular
surface. Thus, unmineralized bone represents a sizable fraction
of trabecular bone volume. The smooth contour of the osteoid-
marrow interface is in striking contrast to the irregular interface
between osteoid and mineralized bone which reflects past
resorbing activity. Occasionally, woven bone can be seen
buried within the trabecules indicating past high bone turnover.
In adynamic uremic bone disease, the bone volume is fre-
quently reduced. In low turnover osteomalacia, total bone
volume may vary, whereas, the mineralized bone volume is
always low. Osteomalacic bone is prone to deformity and both
types are subject to fractures.
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Mixed uremic osteodystrophy (Fig. 3A, B). Mixed uremic
osteodystrophy lacks a dominant pathogenic cause. Instead,
this type of renal bone disease is caused primarily by hyper-
parathyroidism and defective mineralization with or without
decreased bone formation. These features may coexist in vary-
ing degrees in different patients. This form is seen in the
majority of patients (45 to 80%) on dialysis and in most patients
with end-stage renal failure.
The number of osteoclasts is usually increased. The remod-
elling sites are increased in number and they are heterogeneous.
Active foci with numerous cells, woven osteoid seams and
peritrabecular fibrosis coexist with adjacent lamellar sites with
a more reduced activity. The accumulation of osteoid with
normal or increased thickness of osteoid seams is, therefore,
due to an increase in production of lamellar or woven osteoid.
The active mineralizing surfaces are increased in woven bone
with an increase in mineralization rate and diffuse labelling,
whereas, in lamellar bone, the mineralization surfaces may be
reduced with a decreased mineral apposition rate.
The bone volume is extremely variable in this group and
depends upon the dominant pathogenic cause.
Aluminum-related bone disease. In bone, aluminum is depos-
ited linearly at the bone-osteoid interface and within the boney
trabecules in a diffuse or linear manner [109—Ill]. Nephrolo-
gists continue to erroneously equate aluminum-related bone
disease with low-turnover osteomalacic or adynamic bone
disease. In fact, aluminum related bone disease can be super-
imposed on any of the three previously described histologic
groups. This has important implications for the management of
patients suffering from renal osteodystrophy.
Approximately 50% of unselected patients with chronic renal
failure exhibit aluminum deposition in bone [1061. Although
approximately 90% of the patients with low turnover bone
disease present aluminum deposits, this particular type of
osteodystrophy should be seen as the end result of the effects of
aluminum on bone. In addition to this extreme condition,
aluminum deposition can be seen in approximately 50% of
patients with mixed uremic osteodystrophy and in 10 to 15% of
those patients with predominant hyperparathyroid bone dis-
ease. Aluminum deposition should not be regarded as an
epiphenomenon in hyperparathyroid bone disease, but must be
seen as bearing directly upon renal bone disease in light of the
long-term direct and indirect effects of aluminum on bone, its
distribution within bone and other organs, and its interaction
with PTH and l,25(OH)2D3.
Several effects of aluminum overload on mineral metabolism
have been described. Aluminum decreases the secretion of
PTH [112], and there is an inverse relationship between plasma
PTH levels and bone aluminum content [1131 as well as between
plasma levels of aluminum and parathyroid gland weight [1141.
There is much controversy concerning whether PTH protects
[115—123] against aluminum-related bone disease. The occur-
rence of stainable aluminum at the mineralization front is less
frequent in severe hyperparathyroid bone disease than in the
other types of renal osteodystrophy [106, 115, 1161. However,
high serum levels of PTH seem to augment the uptake of
aluminum in bone [117, 119—123]. Indeed, we have found that
patients with severe hyperparathyroid bone disease may have a
higher bone aluminum content than patients with aluminum
related osteomalacia [personal observation, and 1241. In our
studies using uremic dogs, we found (unpublished observation)
that high PTH levels favor the accumulation of aluminum in a
diffuse manner within mineralized bone or at cement lines. In
addition, there is some evidence that parathyroidectomy may
increase the appearance of stainable aluminum at the mineral-
ization front [122, 125—1281. However, increased total bone
aluminum has been associated with elevated PTH levels. This
apparent contradiction suggests a redistribution of aluminum in
bone after parathyroidectomy [1291.
Administration of l,25(OH)2D3 may induce an increase in
serum aluminum levels [130, 1311 and a concomitant decrease in
liver aluminum [130]. The number of l,25D receptors in bone
and intestinal cells is increased [132, 133] without a concomitant
increase in calcium absorption in aluminum intoxicated rats
treated with 1 ,25(OH)2D3 [132]. Our recent acute [134] and
chronic experiments in one and 5/6 nephrectomized dogs indi-
cate that the administration of 1 ,25(OH)2D3 lessens the alumi-
num accumulation in bone. It is of note that despite successful
removal of aluminum from bone with DFO, bone histology does
not normalize and exhibits characteristics of increased parathy-
roid gland activity with or without a concomitant mineralization
defect, an abnormality responsive to 1 ,25(OH)2D3 therapy.
Aluminum administration has been shown to decrease the
serum levels of 1,25(OH)2D [132, 134, 135], and there is some
evidence that aluminum may interfere with the effects of
1 ,25(OH)2D3 on bone cells [1361. Removal of aluminum after
deferoxamine (DFO) therapy might be associated with elevated
levels of calcitriol [137].
In addition to its negative effect on serum PTH and
I,25(OH)2D, aluminum is known to have a direct effect on
crystal growth and maturation [8]. Aluminum interferes with
the mineralization process and with cellular metabolism. Even
though conflicting data exist regarding the effects of aluminum
on osteoblastic proliferation in cell culture contingent upon the
doses of aluminum given and cell lines selected [138—140], it has
been shown in vivo in uremic patients that there is a strong
relationship between the extent of aluminum deposited linearly
at the mineralization front and the level of bone turnover and
mineralization as assessed by histomorphometry [1091. Other
known cellular effects of aluminum are inhibition of enzyme
related replication [141] and interference with the enzymatic
activities of alkaline and acid phosphatase [136], acetylcho-
linesterase [141], hexokinase [142], and calmodulin [143].
Renal osteodystrophy in patients on chronic ambulatory or
cycling peritoneal dialysis
Conflicting data have been reported regarding the evolution
of renal osteodystrophy in adults and children undergoing
peritoneal dialysis. One study reports no change in bone disease
[144], while others indicate amelioration or worsening of the
bone abnormalities, in particular hyperparathyroidism [145,
146].
Recent studies in a larger number of patients [147, 1481,
revealed that the distribution of the different types of renal
osteodystiophy is similar to the distribution found in the
hemodialysis population. However, secondary hyperparathy-
roidism seems to be more difficult to treat in these patients since
the doses of I ,25(OH)2D3 needed to suppress parathyroid
secretion raise serum calcium in the high normal range [1481.
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Osteomalacia is usually associated with aluminum accumula-
tion mainly in patients receiving aluminum-containing phos-
phate binders [148] and occasionally after acute aluminum
contamination of dialysate fluid [149]. Osteomalacia without
aluminum accumulation can persist however if deficiency in
vitamin D is not corrected.
Clinical signs and symptoms
Patients with mild or moderate renal insufficiency are rarely
clinically symptomatic. Clinical problems arising from soft
tissue and vascular calcifications present prior to orthopedic
skeletal problems. Soft tissue or tumoral calcifications, pseu-
dogout and skin calcifications in adult dialysis patients are
clearly related to the magnitude of the calcium-phosphate
product and are responsive to its reduction. In contrast, vascu-
lar calcifications are not related to the calcium-phosphorus
product and do not respond to its normalization [150].
The "red eye syndrome" resulting from inflammatory reac-
tions to and irritation from conjunctival calcifications is seen in
approximately 10 percent of dialyzed patients. If calcifications
occur in the cornea, band keratopathy can be demonstrated by
slit-lamp examination.
Patients in end-stage renal disease requiring dialysis are
prone to mechanical skeletal problems, to include: fractures of
tubular bones, crush fractures of the vertebrae and rib frac-
tures. In long-term dialysis patients, carpal tunnel syndrome
and chronic arthralgias are often associated with /32-microglob-
ulin amyloid deposition in articular and periarticular structures.
The arthralgias are usually bilateral and affect primarily the
shoulders and other joints such as knees, wrists, and small
joints of the hands. Femoral neck fractures due to bone cysts
can occur. There is no uniformly effective therapy; renal
transplantation might be helpful [1511.
Approximately 20% of dialyzed patients have bone pain,
pseudogout, and/or extraosseous calcifications [1501. Proximal
myopathy and muscle weakness are often seen in conjunction
with bone pain. The kidney's impaired endocrine function may
affect the hormonal target organ, striated muscle, where there
are receptors for P1'H and 1,25(OH)2D3 [152, 153]. Muscle
weakness may be aggravated by aluminum's perturbation of
muscle metabolism [154].
Intractable pruritus, periarticular calcifications, soft tissue
calcifications and rupture of the quadriceps are typically seen in
patients with predominant hyperparathyroid bone disease,
whereas, loss of height and spontaneous fractures occur pri-
marily in patients with low turnover osteomalacia. There is a
relationship between low turnover osteomalacia and encepha-
lopathy. The encephalopathy may be sporadic or endemic.
Sporadic encephalopathy is thought to be caused by aluminum
toxicity due to prolonged therapy using phosphate binders
containing aluminum. Endemic encephalopathy may be due to
insufficient water treatment.
Renal osteodystrophy in children and growing individuals
may present with a different clinical picture. Although bone
pain, pseudogout, soft tissue calcifications, conjunctival calci-
ficatjons and serum biochemical changes are generally similar
to those seen in adults, vascular calcifications are quite infre-
quent in children on chronic maintenance dialysis. Children
usually present with growth retardation and may have epiphys-
iolysis characterized by roentgenologicaly slippage of epiphy-




Serum biochemical parameters are of limited diagnostic
value. The parameters are relatively poor predictors of the type
and severity of bone disease. However, they are somewhat
more reliable as a means to identify high- or low-bone turnover
states.
Serum calcium is homeostatically controlled and the integrity
of bone may be sacrificed to maintain serum calcium within the
normal range. Consequently, serum calcium is a poor predictor
of histological features and is not indicative of bone resorption
in renal patients. Spontaneous hypercalcemia or hypercalcemic
episodes during vitamin D therapy are seen in patients with
severe hyperparathyroidism as well as those with aluminum-
related bone disease.
Generally, phosphorus concentrations are not indicative of
the type or severity of renal bone disease. However, patients
with hyperparathyroid osteodystrophy tend to have higher
serum phosphorus because for these individuals the source is
twofold. Phosphorus is derived from intestinal absorption and
released at a higher rate from bone due to the accelerated bone
turnover characteristic of hyperparathyroid bone disease [11].
This may explain why elevated serum phosphorus levels persist
in some individuals despite administration of high doses of
phosphate binders.
The interpretation of levels of total serum alkaline phos-
phatase is limited. Care must be taken to avoid misinterpreta-
tion of normal total alkaline phosphatase levels as indicative of
normal bone turnover or mineralization status. In addition to
problems related to the dual origin of this enzyme (liver and
bone), elevated serum alkaline phosphatase can be seen in
patients with hyperparathyroidism and its characteristic high-
bone turnover state and in patients with low turnover osteoma-
lacia and rickets, diseases with profound mineralization defect.
Measurement of bone alkaline phosphatase is more sensitive
but not widely available. Levels are often elevated, while total
alkaline phosphatase concentrations are normal since bone
alkaline phosphatase represents only 20 to 30% of the total
alkaline phosphatase activity in patients with renal failure.
Parathyroid hormone levels are a relatively good index of
bone remodelling. Parathyroid hormone correlates better with
osteoblastic parameters than osteoclastic indices [331. Parathy-
roid hormone levels are higher in severe hyperparathyroid bone
disease than in low-turnover uremic osteodystrophy. However,
there is a considerable overlap in PTH concentrations between
the different histological types of renal osteodystrophy. Radio-
immunoassays recognizing the N-terminal fragment have a
superior diagnostic value than assays detecting M or C frag-
ments [33, 155]. Optimal interpretation of serum PTH levels
requires concomitant measurement of serum calcium and vali-
dation of the assay by bone histomorphometry. Techniques for
determinations of bioactive PTH levels using a cytochemical
bioassay [156, 157] or a guanyl nucleotide-amplified renal
adenylate cyclase assay [158] have been developed. The utility
of these assays as a predictor of histological types is unknown.
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Bone Gla-protein or osteocalcin is a good predictor of the
number of osteoblasts in bone and permits a distinction be-
tween high and low turnover state of bone [159]. However,
serum levels of BGP lack the sensitivity needed to distinguish
mixed uremic osteodystrophy from the other forms of renal
bone disease.
The levels of 25(OH)D are usually normal in renal patients
receiving standard multivitamin supplementation. Only in cases
of reduction in exposure to sunlight, malnutrition, melanosis
cutis, heavy proteinuria, phenobarbital intake, alcoholism or
advanced liver disease are 25(OH)D levels low and may con-
tribute to bone disease [160]. Levels of l,25(OH)2D are low or
in the low normal range and are of no diagnostic value except
that they may reflect the severity of the bone disease.
Plasma levels of calcitonin have not been proven to be of any
use in predicting renal osteodystrophy [841. This may be due, at
least in part, to the lack of specificity and sensitivity of most
radioimmunoassays employed.
Osteonectin [6], serum procollagen carboxyterminal exten-
sion peptide [161] and plasma tartrate-resistant acid phos-
phatase [162] have not been extensively assayed in patients
with renal failure and their potential diagnostic value is un-
known.
The aforementioned biochemical parameters give informa-
tion about bone turnover and/or bone formation, but none
indicate directly aluminum-related bone changes. Diagnostic
tools used to study aluminum-related bone changes include: (1)
measurement of random serum aluminum levels; (2) deferox-
amine mesylate (Desferalk) infusion test (DFO test) [163]; and,
(3) DFO test combined with measurements of serum PTH levels
[164, 165]. Even though correlations exist between random
serum aluminum levels and the extent of stainable aluminum in
bone, no threshold value has been determined allowing a
clear-cut distinction between patients with and without alumi-
num-related bone disease. The DFO test alone, or in combina-
tion with PTH measurement, may be used as a screening test.
However, only 14% of patients with stainable aluminum at
more than 10% of the trabecular surface can be diagnosed
accurately [1661. Due to the DFO test's large number of false
negative results, bone biopsies are the only reliable means for
unequivocal diagnosis of aluminum deposition in bone.
There is no non-invasive tool to ascertain the diagnosis of
amyloidosis. At the present time, confirmation of diagnosis
requires histological examination of deposition of amyloid
fibriles in the involved organs [151].
Radiologic features and bone densitometrv
Information obtained from skeletal X-rays is limited and
often misleading. Radiologic landmarks appear late in the
course of renal osteodystrophy and X-ray techniques focus on
cortical bone while the early abnormalities of renal bone disease
pertain to cancellous bone. The comparison of X-ray findings
and bone histology indicates that most radiologic signs consid-
ered to be pathognomonic of severe hyperparathyroid bone
disease can be found in any of the three histological types. The
radiologic features suggestive of renal bone disease include
erosion of cortical bone evidenced by subperiosteal, pei-iosteal
and endosteal resorption, cortical striation and cortical thin-
ning. Other characteristics include cortical defects in the skull
("pepper pot skull"), acroosteolysis of the clavicula and cr0-
sion of the terminal finger phalanges. Changes in cancellous
bone are indicated by the rugger jersey appearance of the spine
and ground glass aspect of the skull, ribs, pelvis and metaphysis
of long bones.
These findings indicate that there is, or was, a marked
hyperparathyroid component with increased osteoclastic re-
sorption. That is, no unequivocal information about the current
status of the patient can be obtained. In particular, superim-
posed osteomalacia can be overlooked because resorption
cavities will have been replaced by radiolucent osteoid. Looser
zones are not pathognomonic of osteomalacia since similar
landmarks can be found in fatigue or stress fractures in Os-
teopenic bone, although, in renal patients they are highly
suggestive of a severe, advanced mineralization defect. In
long-standing cases of hyperparathyroidism, pseudocysts and
brown tumors can be visualized on X-rays. Large cystic forma-
tions can be seen in severe amyloidosis, especially in the
shoulder and hips [151]. The association of carpal tunnel
syndrome and lytic lesions of carpal bones is highly suggestive
of amyloidosis.
Bone volume is poorly evaluated by standard X-rays. Bone
density and mineral content of the spine measured by dual-
photon absorptiometry (DPA) and CT-scan have been shown to
correlate with cancellous bone mass in iliac bone as evaluated
by histomorphometry [167]. However, it is of note that both
CT-scan and DPA measure bone mineral density and not bone
mass directly, that is, mineral density may be abnormal without
a corresponding change in total bone mass. This explains why
DPA and CT-scans cannot necessarily distinguish patients with
osteopenia (decrease in bone mass with normal mineral density
per unit volume of bone) from those with osteomalacia (normal
or increased bone mass with diminished mineral density per
unit volume of bone).
Although there is a need for more sensitive, non-invasive
diagnostic methods, baseline bone biopsies in conjunction with
a biochemical profile, X-ray findings, densitometry, and clinical
manifestations, followed by sequential assessment of non-
invasive parameters, provide a means to follow the effective-
ness of any given therapy.
Bone biopsy and mineralized bone histology
At the present time, bone biopsies and mineralized bone
histology still represent the only unequivocal means to evaluate
the severity and the type of renal osteodystrophy. Labelling of
bone with tetracycline prior to biopsy will dramatically improve
the quality of the information provided by histological analysis
and will give information on the mineralization status (Fig. 4).
Processing the bone sample without removal of the mineral
allows distinction between osteoid and mineralized bone. View-
ing the slides under polarized light allows one to distinguish
between the relative amount of lamellar and woven bone and/or
osteoid. In addition to routine staining procedures [Ii] using
Masson-Goldner trichrome, Hematein and Eosin, and so-
lochrome-cyanin, additional stains are used to detect aluminum
(Fig. 5) [168, 169] and iron. Congo red stains are used for
detection of amyloid deposits. Bone specimens can also be used
to measure the mineral content of bone, toxins, and trace
elements, in particular, aluminum.
Bone histomorphometry represents an invaluable research
tool for investigation of pathogenetic factors and documenta-
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tion of the effects of therapies. It is our opinion that the
interpretation of numerical results alone is insufficient for
interpretation of bone changes. Thorough diagnostic assess-
ment of bone and bone marrow by an experienced bone
histopathologist is essential with or without the additional
information provided by histomorphometry.
For research purposes, the quantitative evaluation of param-
eters of bone structure, formation, resorption and dynamics
[11] documents the nature and the amplitude of morphological
changes. Quantitative evaluation of parameters is best achieved
using computerized assisted method [170, 171].
Therapeutic modalities
Long-standing renal osteodystrophy leads to morbidity and
mortality and is not easily amenable to treatment. Because the
effects of renal failure on bone can be observed at a GFR of
approximately 60 mI/mm and renal osteodystrophy progresses
insidiously for several years before patients become sympto-
matic, the need to initiate early preventive measures cannot be
overemphasized and represents the most effective approach.
Preventive measures should be aimed at correcting the early
consequences of the failure of excretory and endocrine kidney
function leading to secondary hyperparathyroidism. This en-
tails the maintenance of normal serum phosphorus and calcium,
and supplementation of the deficient hormone 1 ,25(OH)2D3,
keeping in mind that these abnormalities are related. Ideally,
these measures should be initiated prior to chronic maintenance
dialysis and continued after dialysis has begun.
Control of phosphorus
Dietary phosphate restriction. Patients with early renal fail-
ure typically have normal or low levels of serum phosphorus.
This is misleading, in that their PTH concentration is elevated
and as a result tubular reabsorption of phosphorus is decreased.
Experimental dietary phosphorus restriction was shown to
decrease serum PTH levels, and to increase plasma levels of
l,25(OH)2D [172, 173], total urinary excretion of calcium [173],
intestinal calcium absorption and, occasionally, total and ion-
ized serum calcium concentrations [1721.
Serum phosphorus usually rises when the GFR is 25% of
normal [174]. Therefore, restriction of phosphate intake ap-
pears logical at this stage. This requires a thorough dietary
assessment and advice from a skilled dietician. A regimen of
less than 500 mg of phosphorus per day has been advocated for
prophylaxis [175], but may be nutritionally too restrictive and
inadequate for most patients due in part to concomitant low
protein intake and the risk of phosphorus depletion which may,
in turn, induce osteomalacia. Usually, a daily intake of phos-
phorus of approximately 800 mg should be acceptable with
careful monitoring of phosphate balance.
Phosphate-binding. When the use of intestinal phosphate-
binders is required, the nephrologist is confronted with a
dilemma because the ideal compound has yet to be discovered.
Recently introduced alginate phosphate-binders have yet to
be proven safe and efficient [1761, The efficacy of magnesium
salts is controversial. Some reports show that magnesium
carbonate can be effective, while magnesium oxide and trisili-
cate were ineffective [177—1791. It is of note that magnesium
salts may have deleterious effects on bone mineralization and
the central nervous system. Clinicians choose mostly between
aluminum gels and calcium salts.
The most potent phosphate binders (hydroxide or carbonate)
are those containing aluminum, but one bears the risk of
aluminum intoxication when given at high doses for an ex-
tended period of time, Used in low doses with careful monitor-
ing of serum aluminum levels, these compounds may have a
beneficial effect when given alone or in conjunction with other
phosphate-binders.
Substitution of calcium salts for drugs containing aluminum is
in current practice. Several salts have been introduced in a
more or less empirical manner and found able to bind phospho-
rus [180—1821. (a) Calcium salts such as lactate or gluconate are
not palatable and require an excessive fluid ingestion [183]. (b)
Calcium carbonate is more tolerable and has the potential
beneficial effect to correct hyperphosphatemia, hypocalcemia
and metabolic acidosis [182]. (c) Calcium citrate bears the risk
of increasing aluminum absorption when administered together
with aluminum gels [184—186]. (d) Calcium acetate has recently
been found superior to the other calcium salts for the in vitro
and in vivo binding of phosphorus [187]. Additional studies are
needed to confirm this in renal patients.
Calcium salts are less potent than aluminum phosphate-
binders in decreasing phosphorus levels, and increase the risk
of hypercalcemia and extraosseous calcifications, especially
when given with I ,25(OH)2D3 therapy.
A recent controlled study using calcium acetate has proven
the empiric clinical notion that phosphate-binders should be
given with meals, either immediately before or after a meal or
either at half dose [1811. Ideally, the dose should be tailored to
the phosphorus content of each meal. This approach assures
minimal dietary intake of phosphorus and avoids unnecessary
administration of binder. Studies indicate that ketovalin binds
phosphate as efficiently as calcium carbonate [1881. The thera-
peutic efficacy of phosphate binders with low calcium content
needs further study. It has also been suggested that a combina-
tion of calcium carbonate and ketovalin might be of clinical
value because of the optimal phosphate binding of the two
substances at different pH values [188].
With stringent monitoring of serum aluminum and calcium,
low doses of aluminum gels prescribed in tandem with calcium
salts may currently represent the best approach available until
better phosphate binders are found.
The level of serum phosphorus should be kept in the range of
4.5 to 6 mg/dl. Sustained hyperphosphatemia is not necessarily
related to insufficient dosage of phosphate-binders or noncom-
pliance of the patient, but can be secondary to release of
phosphate from bone in severe hyperparathyroid bone disease.
Removal of phosphorus by dialysis
The dialyzer clearance of phosphorus depends upon the
blood flow and duration of dialysis. The clearance of the
commonly used membranes is relatively poor in hemodialysis
and somewhat superior with peritoneal dialysis. Enhancement
of phosphorus clearance by new dialysis membranes might be
beneficial.
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Control of calcium
Prior to initiation of dialysis, the patient's tendency to
hypocalcemia can be controlled by manipulation of serum
levels of phosphorus and/or 1 ,25(OH),D3 administration.
In dialysis patients, serum calcium levels can be controlled
by manipulation of the dialysate calcium concentration. The
profession's view of optimal dialysate calcium concentration
has changed overtime. Initially, low calcium concentrations (50
to 60 mg/liter) were used. As evidence for secondary hyper-
parathyroid bone disease accumulated, calcium concentrations
were increased [189]. Relatively high concentrations became
the norm. We found that chronic positive calcium balance
without vitamin D therapy seemed to increase soft tissue and
vascular calcification [190]. At the present time, lower dialysate
calcium concentrations are coordinated with high doses of oral
calcium salts used to bind phosphate. Even though this ap-
proach appears to solve the problems associated with therapy
using calcium salts as a phosphate binder, one should bear in
mind that if the balance between calcium removal during
dialysis and oral administration of calcium salts between dialy-
sate treatments is poorly maintained, the patient risks either
transient, increased parathyroid gland activity or extraosseous
calcifications.
The approach of using a calcium-free dialysate with intrave-
nous calcium infusion represents a clinical experiment which, if
further tested, might be an option for the exceptional patient
with extreme difficulties in controlling serum calcium [1911.
I ,25(OH)2D3 supplementation
The prevention of renal osteodystrophy using renal hormone
l,25(OH)2D3 supplement has been in use since 1972.
From 1972 through August 1989, approximately 330 patients
with mild to moderate renal insufficiency have been treated with
l,25(OH)2D3. Beneficial effects on prevention of renal bone
disease, reversal of secondary hyperparathyroidism and in-
creased growth velocity in children have been observed [192,
1931.
However, the cost of the metabolite and concern regarding a
potential negative effect on renal function has hampered its
widespread prophylactic use. The studies that suggested a delete-
rious effect on kidney function (decreased GFR) were uncon-
trolled prospective studies using high doses of I ,25(OH),D3 [194—
1981. Double-blind placebo controlled trials or prospective studies
using smaller doses failed to demonstrate this deleterious effect
[199—201] when hypercalciuria and hypercalcemia were closely
monitored. However, it has been found that even low doses of
1 ,25(OH)2D3 given for one year may suppress bone turnover in
some patients [201], a finding that calls for lower doses andlor
intermittent therapy as an alternative.
In dialyzed patients, approximately 170 reports (850 patients)
have been published on the effects of 1 ,25(OH),D3 given at doses
varying from 0.027 to 3.5 pg/day in adults and 0.375 to 62 ng/day
in children. Duration of therapy ranged from four days to ten
years. These studies were usually designed as prospective or
retrospective, and few were double-blind placebo controlled. In
addition, most studies were conducted before aluminum was
recognized as a pathogenetic factor for renal osteodystrophy, and,
therefore, information on aluminum in serum, dialysate or bone is
given in only a few reports.
Most studies revealed a beneficial effect of I ,25(OH),D3 on
biochemical, radiological and histological signs of hyperpara-
thyroid bone disease [202, 2031. The drug's effect on the
osteomalacic component of renal osteodystrophy is somewhat
difficult to establish because of the uncertain contribution of
aluminum.
Hypercalcemia is a rather common side-effect of daily
l,25(OH)2D3 therapy. Alternative approaches such as "pulse
therapy" with high doses given twice weekly at the end of
dialysis [204] or modulation of calcium supplement, dialysate
calcium, along with doses of l,25(OH)2D3 [2051, were shown to
be efficient in decreasing PTH secretion with less hypercalce-
mia.
Studies suggest that the route of administration bears directly
upon the efficacy of drug therapy. Intraperitoneal administered
calcitriol has been advocated [206] but does not seem to be
more advantageous than orally administered calcitriol [207].
Intravenous administration of I ,25(OH)2D3 suppresses the lev-
els of P1'H with decreased incidence of hypercalcemia [2081.
Higher peak levels and/or greater bioavailability of intravenous
calcitriol may account for an enhanced biologic effect of the
intravenous administered 1 ,25(OH)2D3.
Few long-term controlled studies have been reported on
selected patients with predominant hyperparathyroid bone dis-
ease who became hypercalcemic with oral I ,25(OH)2D3 therapy
[207, 209-211]. The anecdotal clinical observation of rapid
metastatic calcification with intravenous calcitriol occurring
with a calcium and phosphorus product above 80 [212] indicates
that similar precautions are needed for i.v. and oral calcitriol
administration. Clearly, further studies are needed to assess the
efficacy and safety of i.v. 1,25(OH)2D3 in patients with renal
failure, and to answer whether the beneficial effect on hyper-
parathyroidism might be limited when severe "autonomous"
hyperparathyroidism with increased parathyroid cell mass pre-
vails.
In addition, recent reports of in vitro experiments that
suggest a potential effect of calcitriol on lipid accumulation in
human monocyte derived macrophages [213, 2141 deserve fur-
ther in vivo studies to prove or disprove this potentially
disturbing side effect.
Because 24,25(OH)2D was alleged to play a role in calcium
metabolism [215, 2161, clinical trials and experimental studies
using 24,25(OH)2D alone or in combination with 1 ,25(OH),D3
were undertaken [2 17—220]. The results of these studies do not
support the notion that 24,25(OH)2D has a prophylactic or
therapeutic effect on renal osteodystrophy. However, it was
found that when administered with l,25(OH),D3, the occur-
rence of hypercalcemia decreased and the serum level of
l,25(OH),D fell [219, 221].
The hypothesis that 24,25(OH)2D increases the l,25(OH),D3
receptor occupancy and, therefore, enhances its physiologic
activity has been at least partially disproven. Recent findings
point to a 24.25(OH),D mediated increase in the metabolic renal
clearance rate of calcitriol [222]. Therefore, the effect of
24,25(OH),D on serum concentrations of I ,25(OH),D appears
to result from an increased degradation.
The most promising future approach would be to isolate the
positive effect of I ,25(OH)2D3 on osteoblastic receptors from
those on intestinal receptors. Our experience in testing new
vitamin D metabolites suggests that the ideal compound should
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have: (1) a positive effect on bone while avoiding a profound
decrease in bone turnover, as well as (2) a moderate effect on
parathyroid glands and intestinal calcium absorption.
We do not think that prevention or treatment of hyperpara-
thyroidism and avoidance of aluminum accumulation will com-
pletely eliminate renal bone disease, since we have shown that
bone cells do not function properly in the presence of normal
levels of parathyroid hormone and low levels of 1,25 Vitamin D
[223]. Further studies are needed to determine whether alter-
ations of the various hydroxyl groups of the vitamin D sterol
can accomplish this.
The recent study using 22-oxa-calcitriol [224] revealed a
profound suppressive effect on parathyroid gland secretion and
calcium absorption and no or little in vitro effect on bone. This
compound could therefore be useful in the short-term manage-
ment of severe hyperparathyroidism. However, the dramatic
decrease in parathyroid hormone production with a concomi-
tant decrease in l,25(OH)2D would lead, over time, to a
profound decrease in bone turnover and to adynamic bone
disease.
The discovery of partial control of parathyroid secretion by J
blocker and H2 antagonists has stimulated clinical trials using
these substances [225, 226]. Available long-term results are not
convincing.
Removal of aluminum
Several methods are available for removal of aluminum from
bone. Any therapeutic maneuver that lowers plasma aluminum
levels and creates a concentration gradient across the bone-
extracellular fluid membrane will be able to move aluminum
from bone to blood
In plasma, approximately 20% of the aluminum is non-protein
bound and ultrafiltrable. In hemodialyzed patients, this means
that a plasma level of at least 50 slIliter is needed to reach an
osmotic gradient between blood and dialysate [227, 228] since
dialysate may contain 5 to 10 jsg/liter of aluminum after reverse
osmosis.
The simplest method seems to be to completely withdraw the
aluminum containing phosphate binders and to replace them
with calcium salts. However, frequent hypercalcemia is en-
countered necessitating a lowered calcium dialysate that may in
itself cause problems (vide supra). The elimination of excessive
aluminum from bone through normal turnover, that is, without
chelation, would take years. Certain hemodialysis membranes,
such as polysulfone or polyacrylonitrile membranes, may have
higher aluminum clearances than others. Aluminum clearances
achieved with peritoneal dialysis may be greater than with
hemodialysis due in part to loss of protein-bound aluminum
[229]. At present, it is not known whether CAPD is preferable
to hemodialysis in removing aluminum.
The use of a chelator increases the complex bound fraction of
aluminum and facilitates its removal through dialysis. A highly
specific and entirely safe chelator of aluminum does not exist.
EDTA lacks specificity and binds calcium. Deferoxamine (Des-
feral', Ciba Geigy, Summit, New Jersey, USA) is presently the
best chelator of aluminum available.
Deferoxamine has been proven relatively safe but rare ocular
complications such as cataracts, altered color vision, night
blindness or scotoma have been reported [230]. Episodes of
hypotension can occur during therapy and are usually easily
reversible; in some cases, however, they have been accompa
nied by angina. The association between Deferoxamine therapy
and infections has been the subject of an abundant and contro-
versial literature during the last few years. Deferoxamine is
thought to act as siderophore and therefore promotes bacterial
and fungal infections [231, 232]. Although numerous case
reports of bacteremia and mucormycosis occurring with Defer-
oxamine (DFO) therapy have been published, recent large
surveys did not confirm that DFO increases the risk of bacter-
emia in dialysis patients [233], and in vitro studies did not find
any stimulative effects of DFO with or without iron and
aluminum on the growth of Mucorales [234]. The relationship
between DFO therapy and infections certainly requires further
investigation. Consequently, careful documentation of alumi-
num overload is required before long-term DFO therapy is
begun.
After initiation of DFO therapy, increases in serum aluminum
levels are observed indicating the translocation of aluminum
from bone and other organs into the blood. With continuation of
chronic intermittent therapy, a saw tooth pattern of blood
aluminum levels before and after infusion is customarily ob-
served, with a trend toward baseline values after three to twelve
months depending upon the extent of initial aluminum overload
[163]. When no further increases in serum aluminum levels are
seen and, more importantly, a zero dialysance is observed.
therapy should be discontinued to avoid chelation of other trace
metals [235].
During DFO therapy, parathyroid hormone levels may rise
[163], or be higher at any given serum calcium (change in
calcium set-point and maximum PTH inhibition) [236]. Defer-
oxamine seems, therefore, to enhance the PTH secretion per
individual parathyroid cell [236].
At this point, bone biopsies are helpful for documentation of
removal of aluminum from bone. Biopsies assist the clinician in
diagnosis of the new underlying renal osteodystrophy since low
turnover bone disease can be transformed into mixed uremic
osteodystrophy or the latter into predominant hyperparathyroid
bone disease.
Muscle pain and weakness are usually the first symptoms to
improve followed by improvement in bone pain. Usually, serum
PTH and alkaline phosphatase levels increase. Development of
pruritus is not unusual paralleling the increase in PTH levels.
Transient episodes of hypocalcemia or diminished serum
calcium levels may be encountered necessitating administration
of 1,25(OH)7D3. The most frequently encountered side-effect is
transient hypotension due to the histamine-mediated vasodila-
to'ry effect of the drug and an infusion rate exceeding 15 mg/kg
body wt/hr. Nausea, vomiting and neuromuscular excitability
are usually transient.
Although more long-term placebo controlled studies are
necessary, it is obvious that DFO therapy is efficient in most
cases in removing aluminum and is acceptably safe. However,
considerable controversy exists regarding the dose, time, route
and frequency of infusions of DFO. The optimal dose is 15 to 20
mg/kg body wt infused over a two hour period, three times per
week. Infusions of DFO at the end of dialysis are potentially
more efficient since it allows the chelator to act longer. How-
ever, this bears the risk of inducing long-standing high levels of
blood aluminum which could be redistributed to the brain
causing acute encephalopathy. Intramuscular injections of I g
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of DFO 12 hours before dialysis once weekly have also been
suggested [237]. In high risk patients, the dose and the fre-
quency of injections might have to be reduced.
It is not known if aluminum can reaccumulate in bone after
successful chelation therapy despite low dose (or absence of)
administration of aluminum-containing phosphate binders, and
whether other substances are removed during chelation therapy
inducing insidious deficiencies.
Trials using hemofiltration without dialysis, plasma exchange
or sorbent hemoperfusion have been disappointing when em-
ployed without additional systemic or extracorporeal DFO
therapy. The added expense and the logistical problems of using
special cartridges with microencapsulated carbon (AlucartR;
National Medical Care, Rockleigh, New Jersey, USA) [238,
239] or DFO coating (Al/Fe ClarkR Specific; Clark Research
and Development, Inc., Folsom, Louisiana, USA) limits their
application to severe aluminum toxicity where time is of the
essence.
Parathyroidectomy
In the past, the surgical reduction of parathyroid glands has
been overzealous. High levels of PTH (especially C or M
terminal) and hypercalcemia should not prompt the clinical
nephrologist to recommend parathyroidectomy. The threat to
fragile patients posed by anesthesia is calculable and well
known. Parathyroidectomy should represent the treatment of
last resort and should always be preceded by a careful assess-
ment of aluminum loading and histological verification of the
diagnosis by bone biopsy. Its indications must be restricted to
refractory calciphylaxis, idiopathic disseminated skin necrosis,
and marked sustained hypercalcemia without other identifiable
causes (in particular, sarcoidosis). Only when all available
therapeutic modalities have failed should parathyroidectomy be
recommended.
There is much controversy regarding the optimal choice of
the type of parathyroidectomy to be performed [240, 241].
Three surgical modalities are currently used: subtotal and total
parathyroidectomy and total parathyroidectomy with auto-
transplantation.
Although all three surgical approaches are usually followed
by short-term clinical and biochemical improvement, persistent
severe hyperparathyroidism can be encountered due to failure
to resect all parathyroid gland tissue. Long-term results show a
non-negligible incidence of recurrent hyperparathyroidism, es-
pecially with subtotal and total parathyroidectomy with auto-
transplantation. In these instances, localization of the hyperac-
tive parathyroid fragment can become challenging. Malignant
transformation of residual or transplanted tissue has also been
described especially in cases of prior neck irradiation [242].
Long-standing severe hypoparathyroidism remains a major risk
chiefly after total parathyroidectomy. Long-term supplementa-
tion in calcium and/or l,25(OH)2D3 is then required and a
dramatic decrease in bone turnover can occur leading to ady-
namic bone disease and increased risk of extraosseous calcifi-
cations.
Development of alternative, less invasive approaches, such
as reduction of parathyroid gland cellular mass by percutaneous
injection of absolute ethanol with assisted localization of para-
thyroid gland by ultrasound, seem promising [243, 244]. In any
event, particular, careful post-surgical follow-up is needed as
clinical reports show that patients appear particularly prone to
accumulate aluminum in bone after parathyroidectomy [127,
128, 245, 246]. Institution of postsurgical I,25(OH)2D3 therapy
should be delayed if widespread extraosseous calcifications are
present. Maintenance of serum calcium with individually dosed
calcium supplements following surgery should help mobilize
extraosseous calcifications and facilitate improved function of
the transplanted gland cells.
Despite the recent advances in the understanding of patho-
genetic mechanisms and the introduction of new, potentially
helpful therapeutic regimen, there is no uniformly accepted
management of the metabolic bone disease(s) of patients with
chronic renal failure. This review provides a rational therapeu-
tic approach. However, it should be noted that some of the
drugs recommended and used by nephrologists have not been
approved by the Food and Drug Administration for the given
indication. New therapeutic approaches should not be ad-
vanced hastily, and experimental animal studies and long-term
prospective controlled trials in patients are imperative before
general recommendations can be given. Any therapeutic regi-
men should be tailored to the clinical, biochemical and histo-
logical derangements of the individual patient, and careful
follow-up is needed.
Prophylactic measures should be the first priority in manage-
ment of renal osteodystrophy. Long-term studies on the effects
of prophytaxis will show whether the quality of life and longev-
ity of dialysis patients improve.
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